NASDAQ:QLGN Qualigen Therapeutics Q3 2025 Earnings Results & Report $1.80 +0.03 (+1.69%) As of 10/9/2026 Qualigen Therapeutics reported Q3 2025 earnings on November 14, 2025. The company reported EPS of -$4.68. Research:ProfileEarnings History Earnings Announcement Details QuarterQ3 2025Report DateNovember 14, 2025TimeAfter Market Closes Qualigen Therapeutics EPS ResultsActual EPS-$4.68Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate4 of last 5 quartersQualigen Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Qualigen Therapeutics Q3 2025 Earnings FAQ Did Qualigen Therapeutics beat earnings estimates for Q3 2025? Qualigen Therapeutics (NASDAQ:QLGN) reported earnings of -$4.68 per share for Q3 2025. The report was announced on Friday, November 14, 2025. Qualigen Therapeutics Earnings HeadlinesQualigen Therapeutics Signs Exclusive License Agreement with the University of Louisville, Plans to Develop AS1411 for the Treatment of COVID-19December 13, 2025 | cnn.comQualigen Therapeutics Rebrands to AIxCrypto HoldingsNovember 17, 2025 | msn.comINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and built in a matter of weeks. James Altucher says the site could go live as soon as October 21 and has put together a free presentation explaining what is happening inside and why the timing matters.October 12 at 1:00 AM | Paradigm Press (Ad)Qualigen Therapeutics stockholders approve all proposals with majority voteNovember 17, 2025 | msn.comFaraday Future Becomes Majority Shareholder in Qualigen Therapeutics, Preparing for Corporate Rebranding and Strategic Transformation on November 20November 16, 2025 | quiverquant.comQQualigen Therapeutics Stockholders Approve All Proposals with Majority Vote; Company to Rebrand as AIxCrypto Holdings, Inc. (Nasdaq: AIXC) Following November 20 Nasdaq Ceremony and Announces Transition into AI × Web3 StrategyNovember 16, 2025 | globenewswire.comSee More Qualigen Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Qualigen Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Qualigen Therapeutics and other key companies, straight to your email. Email Address About Qualigen TherapeuticsQualigen Therapeutics (NASDAQ:QLGN) is a clinical-stage biotechnology company focused primarily on developing therapies for cancer and other serious diseases. The company’s lead therapeutic program is QN-302, a small-molecule drug candidate being investigated for its potential to treat solid tumors, including pancreatic cancer. Qualigen is also developing additional oncology-focused programs, including QN-247, an aptamer-based candidate designed to target nucleolin, a protein associated with cancer-cell growth and survival. These programs remain subject to clinical and regulatory development, and their ultimate safety and effectiveness have not been established. The company traces its history to Qualigen, Inc., a developer of diagnostic products and instruments. Through its wholly owned subsidiary, Qualigen continues to support diagnostic activities involving the FastPack system, an automated platform used with certain clinical laboratory tests. Qualigen Therapeutics is headquartered in San Diego, California, and its operations are directed toward biotechnology research, clinical development and diagnostic products serving healthcare markets.View Qualigen Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Retail Picks to Watch as the Holiday Shopping Season NearsMarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsC.H. Robinson Bets Its AI Story on RXO—But the Market Isn't SoldApplied Digital’s Hidden Moat Could Unlock Massive Upside Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
